Cobenfy, a brand new drug made by means of Bristol Myers Squibb and authorized by means of the FDA ultimate week, triggers muscarinic receptors as a substitute of dopamine receptors. It is the first schizophrenia remedy to take action.
Bristol Myers Squibb
cover caption
toggle caption
Bristol Myers Squibb
Cobenfy, a brand new drug made by means of Bristol Myers Squibb and authorized by means of the FDA ultimate week, triggers muscarinic receptors as a substitute of dopamine receptors. It is the first schizophrenia remedy to take action.
Bristol Myers Squibb
For the previous 70 years, schizophrenia remedies all focused the similar chemical: dopamine. Whilst that works for some, it reasons brutal unintended effects for others. An antipsychotic drug authorized ultimate month by means of the FDA adjustments that. It triggers muscarinic receptors as a substitute of dopamine receptors. The drug is the results of a possibility clinical discovering … from a learn about that wasn’t even all for schizophrenia. This episode, host Emily Kwong and NPR pharmaceutical correspondent Sydney Lupkin dive into the place the drug originated, the way it works and what it could shift for other people with schizophrenia. Learn extra of Sydney’s reporting in this new remedy.
This episode used to be produced by means of Hannah Chinn and edited by means of our showrunner, Rebecca Ramirez. The information have been checked by means of Tyler Jones. The audio engineer used to be Maggie Luthar. Pay attention to Brief Wave on Spotify and Apple Podcasts. Pay attention to each and every episode of Brief Wave sponsor-free and fortify our paintings at NPR by means of signing up for Brief Wave+ at plus.npr.org/shortwave. This episode used to be produced by means of Hannah Chinn and edited by means of Rebecca Ramirez. It used to be fact-checked by means of Tyler Jones. Maggie Luthar used to be the audio engineer.
